NFL BIOSCIENCES (EPA:ALNFL) | WebDisclosure

Basculer en Français

8611	Companies
141742	Keywords
77650	Articles
75757	Press releases

Home
Companies
NFL BIOSCIENCES

BRIEF

published on 04/11/2025 at 17:50, 2 days 3 hours ago

NFL Biosciences Reveals 2024 Results and Updates Clinical Progress

Biopharmaceutical Company Smoking Cessation Phase 3 Trial Financial Results 2024 NFL-101 Development
BRIEF

published on 04/11/2025 at 17:50, 2 days 3 hours ago

NFL Biosciences dévoile son bilan 2024 et avance vers la phase 3 du NFL-101

NFL Biosciences Sevrage Tabagique Trésorerie Phase 3 Résultats Financiers 2024
REGULATED PRESS RELEASE

published on 04/11/2025 at 17:45, 2 days 3 hours ago

NFL Biosciences presents its 2024 annual results and provides an update on its clinical program
NFL Biosciences presents 2024 annual results and clinical program update. NFL-101 phase 2 efficacy, innovative action with CEA, Phase 3 study plans, financing strategy, low cash burn until Q4 2025

NFL Biosciences NFL-101 Phase 3 Study 2024 Annual Results Clinical Program Update
REGULATED PRESS RELEASE

published on 04/11/2025 at 17:45, 2 days 3 hours ago

NFL Biosciences présente ses résultats annuels 2024 et fait le point sur son programme clinique
NFL Biosciences présente ses résultats annuels 2024 et fait le point sur son programme clinique. Avancées pour le traitement First in class NFL-101 contre le tabagisme, études cliniques positives et stratégie de développement clinique structurée

NFL Biosciences Résultats Annuels NFL-101 Tabagisme Études Cliniques
BRIEF

published on 03/24/2025 at 17:50, 20 days 3 hours ago

NFL Biosciences Confirms NFL-101's Efficacy in Tobacco Addiction Treatment

NFL-101 Phase 2 Study Tobacco Addiction Immunological Analysis Continuous Abstinence
BRIEF

published on 03/24/2025 at 17:50, 20 days 3 hours ago

NFL Biosciences confirme l'efficacité de son traitement contre l'addiction au tabac

Traitement Anti-tabac Phase 2 CESTO II Immunoglobulines Anti-tabac Efficacité NFL-101 Biomarqueur D'abstinence
REGULATED PRESS RELEASE

published on 03/24/2025 at 17:45, 20 days 3 hours ago

NFL Biosciences présente les résultats de l'analyse immunologique de son étude de phase 2 CESTO II confirmant l'efficacité de NFL-101, son traitement first in class contre l’addiction au tabac
NFL Biosciences présente les résultats positifs de l'étude de phase 2 CESTO II confirmant l'efficacité de NFL-101, traitement innovant contre l'addiction au tabac

NFL Biosciences NFL-101 Efficacité Étude De Phase 2 Addiction Au Tabac
REGULATED PRESS RELEASE

published on 03/24/2025 at 17:45, 20 days 3 hours ago

NFL Biosciences presents the immunological analysis results of its phase 2 CESTO II study confirming the efficacy of NFL-101, its first-in-class treatment for tobacco addiction
NFL Biosciences presents immunological analysis results of phase 2 CESTO II study confirming efficacy of NFL-101 for tobacco addiction. Association between anti-tobacco IgG increase and continuous abstinence strengthens evidence

NFL Biosciences NFL-101 Tobacco Addiction Immunological Analysis CESTO II Study
BRIEF

published on 03/05/2025 at 17:50, 1 month 8 days ago

NFL Biosciences annonce son agenda financier pour 2025

NFL Biosciences Résultats Annuels Assemblée Générale Biopharmaceutique Agenda Financier 2025
BRIEF

published on 03/05/2025 at 17:50, 1 month 8 days ago

NFL Biosciences Releases 2025 Financial Agenda

NFL Biosciences Addiction Treatment Biopharmaceutical Botanical Drugs Financial Agenda 2025

1 2 ... 8

Accesswire

Published on 04/12/2025 at 15:45, 1 day 5 hours ago

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presid
Published on 04/12/2025 at 02:00, 1 day 19 hours ago

Battery X Metals Announces Provisional Patent Application with United States Patent & Trademark Office for Lithium-Ion Battery Rebalancing Technology Innovations
Published on 04/12/2025 at 00:10, 1 day 21 hours ago

Applied Minerals, Inc. Files Motion to Approve Disclosure Statement
Published on 04/12/2025 at 00:00, 1 day 21 hours ago

Ur-Energy Releases 2024 Year End Results
Published on 04/11/2025 at 23:45, 1 day 21 hours ago

Gold Terra Closes First Tranche of Financing Package with Support from Osisko Gold Royalties

View all ACCESSWIRE

EQS Group

Published on 04/11/2025 at 21:45, 1 day 23 hours ago

OPPO Unveils Agentic AI Initiative at Google Cloud Next 2025, Showcasing Innovations and Leadership in AI Experiences
Published on 04/11/2025 at 18:40, 2 days 2 hours ago

AGM 2025 - Bossard Holding AG Press Release
Published on 04/11/2025 at 18:38, 2 days 2 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/11/2025 at 18:23, 2 days 3 hours ago

EQS-Adhoc: Cherry SE: Cherry SE recognizes asset impairment for 2024; updates adjusted EBITDA margin for fiscal year 2024
Published on 04/11/2025 at 18:10, 2 days 3 hours ago

Kaufman & Broad SA: 2025, 1ST QUARTER RESULTS

Les Echos

Published on 04/11/2025 at 18:30, 2 days 2 hours ago

Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Published on 04/11/2025 at 18:30, 2 days 2 hours ago

Reclassement d'actions au sein du concert familial Feuillet sans incidence sur le contrôle de la société
Published on 04/11/2025 at 18:00, 2 days 3 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/03/2025
Published on 04/11/2025 at 18:00, 2 days 3 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
Published on 04/11/2025 at 17:50, 2 days 3 hours ago

Mise à disposition du Rapport Financier Annuel 2024

View all LES ECHOS COMFI WIRE